Challenges for HCV Vaccine Development in HIV–HCV Coinfection

From Expert Review of Vaccines

Challenges for HCV Vaccine Development in HIV–HCV Coinfection

Mélanie Lambotin; Heidi Barth; Christiane Moog; François Habersetzer; Thomas F Baumert; Françoise Stoll-Keller; Samira Fafi-Kremer

 

Posted: 09/07/2012; Expert Rev Vaccines. 2012;11(7):791-804. © 2012 Expert Reviews Ltd.

Expert Commentary
Full text available at Medscape
*Free registration required

HCV-related liver diseases have become one of the leading causes of hospitalization and death in HIV-infected persons in the western world where HAART is widely available. PEG-IFN/RBV HCV treatment has a poor outcome in coinfected individuals and the potential high-risk toxicity of DAAs needs to be further evaluated in HIV–HCV-coinfected patients. DAAs use in HIV–HCV-coinfected patients may increase the proportion of hepatitis C individuals harboring non-HCV genotype 1 or drug-resistant HCV variants. Over time a reservoir of HCV genotype 1 patients will accumulate in developing countries where hepatitis C treatment is not easily affordable and HIV therapy remains the primary health issue for the coinfected patients. For all these reasons there is an urgent need to develop HCV vaccines.

Abstract and Introduction

Epidemiology of HCV in HIV-infected Individuals

Natural History of HCV Infection in HIV-coinfected Patients

Immunological Determinants of HCV Clearance

Impact of HIV on HCV-specific Immune Responses

HIV & HCV Treatment in HIV–HCV-coinfected Patients

HCV Vaccine Approaches: Current Status

Prophylactic Vaccines

Therapeutic Vaccines

HCV Vaccine Development: The Challenge of HIV–HCV Coinfected Patients

Conclusion

Expert Commentary

Five-year View